+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Peptide Antibiotics Market by Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), Disease (Blood Stream Infections, HABP/VABP, Skin Infections), Route of Administration, Distribution Channel - Forecast 2024-2030- Product Image
Global Peptide Antibiotics Market by Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), Disease (Blood Stream Infections, HABP/VABP, Skin Infections), Route of Administration, Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Peptide Antibiotics Market by Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), Disease (Blood Stream Infections, HABP/VABP, Skin Infections), Route of Administration, Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666281
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptide Antibiotics Market size was estimated at USD 5.11 billion in 2023, USD 5.58 billion in 2024, and is expected to grow at a CAGR of 9.74% to reach USD 9.80 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Peptide Antibiotics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Peptide Antibiotics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Peptide Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly & Company, Eugia US LLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Novo Holdings A/S, Pfizer Inc., Sanofi S.A., Savara Inc., Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.

Market Segmentation & Coverage

This research report categorizes the Peptide Antibiotics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Non-Ribosomal Synthesized Peptide Antibiotics
    • Ribosomal Synthesized Peptide Antibiotics
  • Disease
    • Blood Stream Infections
    • HABP/VABP
    • Skin Infections
  • Route of Administration
    • Injectable
    • Oral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Peptide Antibiotics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Peptide Antibiotics Market?
  3. What are the technology trends and regulatory frameworks in the Peptide Antibiotics Market?
  4. What is the market share of the leading vendors in the Peptide Antibiotics Market?
  5. Which modes and strategic moves are suitable for entering the Peptide Antibiotics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Peptide Antibiotics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of diseases such as bacterial skin, blood stream, and hospital acquired infections
5.1.1.2. Rising need for peptide antibiotics in hospitals and clinics
5.1.1.3. Improvement in healthcare infrastructure facility
5.1.2. Restraints
5.1.2.1. Stringent reimbursement policy
5.1.3. Opportunities
5.1.3.1. Rising product approvals and product launches and R&D initiatives
5.1.3.2. Emerging use in regeneration of skin/bone, prevention of implant-associated infections, cancer therapy and gene delivery
5.1.4. Challenges
5.1.4.1. Concerns related to instability and toxicity of peptide antibiotics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Peptide Antibiotics Market, by Type
6.1. Introduction
6.2. Non-Ribosomal Synthesized Peptide Antibiotics
6.3. Ribosomal Synthesized Peptide Antibiotics
7. Peptide Antibiotics Market, by Disease
7.1. Introduction
7.2. Blood Stream Infections
7.3. HABP/VABP
7.4. Skin Infections
8. Peptide Antibiotics Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical
9. Peptide Antibiotics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Peptide Antibiotics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Peptide Antibiotics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Peptide Antibiotics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. AbbVie Inc.
14.1.3. Dr. Reddy’s Laboratories Ltd.
14.1.4. Eli Lilly & Company
14.1.5. Eugia US LLC
14.1.6. Fresenius SE & Co. KGaA
14.1.7. GlaxoSmithKline PLC
14.1.8. Merck & Co., Inc.
14.1.9. Novartis AG
14.1.10. Novo Holdings A/S
14.1.11. Pfizer Inc.
14.1.12. Sanofi S.A.
14.1.13. Savara Inc.
14.1.14. Teva Pharmaceutical Industries Ltd.
14.1.15. Theravance Biopharma
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. PEPTIDE ANTIBIOTICS MARKET RESEARCH PROCESS
FIGURE 2. PEPTIDE ANTIBIOTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PEPTIDE ANTIBIOTICS MARKET DYNAMICS
FIGURE 7. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 10. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. PEPTIDE ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. PEPTIDE ANTIBIOTICS MARKET SIZE, BY NON-RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PEPTIDE ANTIBIOTICS MARKET SIZE, BY RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 9. PEPTIDE ANTIBIOTICS MARKET SIZE, BY BLOOD STREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PEPTIDE ANTIBIOTICS MARKET SIZE, BY HABP/VABP, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PEPTIDE ANTIBIOTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 35. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 39. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 57. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 61. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 69. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 93. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 106. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 110. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 114. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 130. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 142. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 146. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 150. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 166. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 178. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 189. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 190. PEPTIDE ANTIBIOTICS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly & Company
  • Eugia US LLC
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Savara Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.8 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Peptide Antibiotics Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F - Product Image

Peptide Antibiotics Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

  • Report
  • 190 Pages
  • Global
From
Peptide Antibiotics Global Market Report 2024 - Product Image

Peptide Antibiotics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Peptide Antibiotics Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Peptide Antibiotics Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 115 Pages
  • Global
From
2023 Global Forecast for Peptide Antibiotics Marke (2024-2029 Outlook) - High Tech & Emerging Markets Report - Product Image

2023 Global Forecast for Peptide Antibiotics Marke (2024-2029 Outlook) - High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
21st Century Challenges in Antimicrobial Therapy and Stewardship - Product Image

21st Century Challenges in Antimicrobial Therapy and Stewardship

  • Book
From

About the Peptide Antibiotics Market

Peptide antibiotics are a type of antibiotic derived from peptides, which are short chains of amino acids. They are used to treat a variety of bacterial infections, including those caused by Gram-positive and Gram-negative bacteria. Peptide antibiotics are generally more effective than traditional antibiotics, as they are able to target specific bacterial cells and are less likely to cause resistance. They are also less likely to cause side effects, such as nausea and vomiting. Peptide antibiotics are typically administered intravenously or intramuscularly, and can be used in combination with other antibiotics. The peptide antibiotics market is growing rapidly, driven by the increasing prevalence of antibiotic-resistant bacteria and the need for more effective treatments. The market is expected to continue to grow in the coming years, as more research is conducted into the development of new peptide antibiotics. Some companies in the peptide antibiotics market include Merck, Pfizer, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.